RxDoctor Payments Data

Michael Bradshaw, MD

Dermatology · San Diego, CANPI 1861646267

Payments from drug & device makers

$142,971in general payments, 2019–2025

Across 813 payments — averaging $175.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$105K
  • Bristol Myers Squibb$16K
  • E.r. Squibb & Sons, L.L.C.$7K
  • Pfizer$4K
  • Johnson & Johnson$1K
  • Sanofi$1K
  • plus $8K from 30 others

What the payments were for

  • Consulting fees$9,9607%
  • Speaking & faculty fees$108,35576%
  • Travel & lodging$7,5615%
  • Food & beverage$16,37311%
  • Education$7221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,971 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$220,142
Medicare patients
500
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab17$152,810
Cosentyx Sensoready (2 Pens)Secukinumab15$110,165
Dupixent PenDupilumab20$79,835
OtezlaApremilast14$68,308
Dupixent SyringeDupilumab13$46,273
OpzeluraRuxolitinib Phosphate12$23,277
Pimecrolimus13$8,321
Fluocinonide147$5,464
Tacrolimus27$2,902
Ketoconazole119$1,881
Triamcinolone Acetonide175$1,577
Fluorouracil24$1,556
Calcipotriene18$1,518
Doxycycline Hyclate72$1,495
Clindamycin Phosphate27$1,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$105,204$68,30814 claims
Incyte CorporationOpzelura$702$23,27712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.

Other dermatology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →